Electronic cigarette research around the world, particularly in developed countries, is causing concern for those who wish to maintain the ban on electronic cigarettes rather than lift it.
The Daily Mail has reported that British scientists have concluded that electronic cigarettes should be prescribed to help millions of people quit smoking. This could potentially make England the first country in the world to license e-cigarettes as a medical product.
According to the Daily Mail, 40% of those who attempted to quit smoking using a free electronic cigarette were successful within a month.
Professor Caitlin Notley from the University of East Anglia led a pilot project involving 668 patients who were using electronic cigarettes. She stated that, "it led to a successful quit attempt within four weeks for 42% of entrenched smokers. This is particularly important as it can help those who have attempted to quit smoking multiple times but have been unsuccessful, stay away from tobacco.
Professor Notley also stated that the program was "very popular" and acknowledged that "other forms of smoking cessation support are not suitable for everyone." Her team told the nicotine and tobacco research company that they hoped electronic cigarettes would be widely used because they offer nicotine without carbon monoxide or tar.
The daily newspaper reported that this study is extremely significant and has opened up new horizons for the global tobacco market. The NHS stated that electronic cigarettes are not without risks but are better than regular cigarettes.
Previous research has found that 27.2% of people use electronic cigarettes to quit smoking, while 18.2% attempt to use patches and gum.
Last year, regulatory bodies for pharmaceuticals and health products announced that any approved electronic cigarette products would require a prescription from a doctor. "Whether it's the Covid-19 vaccine we've rolled out or the innovative public health measures we've implemented to reduce the risk of severe illnesses, this country is still a global leader in healthcare," said Health Secretary Sajid Javid.
Opening the door to e-cigarettes licensed by the NHS (UK National Health Service) could potentially lead to a significant decrease in the national smoking rate," added Javid.
GoSmokeFree.co.uk conducted a survey of 1,200 respondents to gauge their opinions on the issue. The survey revealed that 35% of participants believed that these products should be available by prescription due to their potential to aid in smoking cessation. Meanwhile, 38% were in favor of banning these products altogether and 45% felt that local anti-smoking laws were not strict enough.
Experts from around the world, particularly those from the World Vapers Alliance (WVA) and WeVape, have praised the UK for embracing science and taking strong measures to reduce tobacco harm. This is something that New Delhi should follow.
Although the World Health Organization (WHO) continues to reject electronic cigarettes and other safer alternatives to nicotine through such measures, the UK has been leading the way in reducing tobacco harms and local smoking rates through its progressive e-cigarette policies.
This is the progress of UK research, where experts are urging London authorities to influence the position of the World Health Organization (WHO). "The UK is at the forefront of reducing harm and has provided an excellent example of effective smoking cessation through e-cigarettes for other parts of the world. Our government has chosen a proven and scientifically-supported path. Before the WHO conference in November, the UK needs to strengthen its commitment to e-cigarettes and encourage other countries to do the same," said Mark Oates, Director of WeVape.
Electronic cigarettes contain nicotine and are not risk-free, but experts from the UK and US have made it clear that regulated e-cigarettes are less harmful than smoking. E-cigarettes that have obtained medicinal licenses must undergo stricter safety checks.
Smoking remains a leading cause of premature death, although smoking rates in the UK are at an all-time low. However, there are still approximately 6.1 million smokers in England.
In 2020, electronic cigarettes were the most popular aid for smokers in the UK trying to quit. They have been shown to be highly effective in supporting those trying to quit smoking, with 27.2% of smokers using e-cigarettes compared to 18.2% using nicotine replacement therapies like patches and gum.
Among individuals attempting to quit smoking, those with the highest success rates include those who used electronic cigarettes to quit smoking, as well as those who utilized local smoking cessation services. From 2020 to 2021, up to 68% of individuals were able to successfully quit smoking.
The example of the United Kingdom needs to be studied carefully in India. For a country with a population exceeding one billion, the Ministry of Health and Family Welfare should work towards minimizing the human and economic losses by reducing the risks associated with tobacco use.
Officials in India's Ministry of Health should now realize that the ban is ineffective and lifting it is necessary, which should not be considered as a means of indulgence. In fact, India must consider humane regulations that are proportional to the risks and take protective measures to prevent abuse.
However, despite the world taking the correct steps, this has not been the case in the past three years. Sadly, India has not changed or made any concessions.
Indians bear a significant burden of tobacco use, with nearly a third of the population relying on some form of it. This has resulted in almost 1.4 million deaths, close to the total population of cities like Ranchi or Jabalpur. Furthermore, the World Health Organization (WHO) has stated that the annual massive loss of $27.5 billion is due to illnesses caused by tobacco use among people aged 35 and above.
The health department has initiated numerous laws to discourage people from smoking, but the most controversial is its irrational decision towards the e-cigarette industry.
Statement
This article is compiled from third-party information and is intended for the purposes of industry exchange and learning.
This article does not represent the opinions of 2FIRSTS, and 2FIRSTS is unable to verify the truthfulness and accuracy of the article's content. The translation of this article is only intended for exchange and research within the industry.
Due to limitations in translation skills, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government regarding any statements and positions related to domestic affairs, Hong Kong, Macau, Taiwan, and foreign affairs.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please kindly contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
